Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

UBS Starts Covering Hythiam With a Buy

UBS Financial started covering Hythiam (HYTM) with a buy rating, explaining that the company owns and licenses a "very promising" new treatment for alcohol, cocaine, and methamphetamine addiction called Prometa protocol.

Analyst Donald Hooker sees more than $8 billion of market opportunity for Hythiam in which there will be little in the way of viable competition. Hooker is willing to assume that Prometa works, based on empirical observations of about 200 patients by clinicians that he considers credible. As more third party data becomes available in 2006, he will will be in a better position to gauge the efficacy of protocol.

blog comments powered by Disqus